Patents by Inventor Darryl C. Rideout

Darryl C. Rideout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIO-AND CHEMO-PROTECTIVE COMPOUNDS
    Publication number: 20230174562
    Abstract: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methy-lamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 8, 2023
    Inventors: Philip S. Schein, Darryl C. Rideout
  • RADIO-PROTECTIVE AND CHEMO-PROTECTIVE SUBSTITUTED THIOLS
    Publication number: 20230138150
    Abstract: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to formula I: The use of these compounds as radio- and chemo-protectors is also described.
    Type: Application
    Filed: November 21, 2022
    Publication date: May 4, 2023
    Inventors: Philip S. Schein, Darryl C. Rideout
  • Radio-protective and chemo-protective substituted thiols
    Patent number: 11566032
    Abstract: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to The use of these compounds as radio— and chemo—protectors is also described.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: January 31, 2023
    Assignees: TONIX PHARMACEUTICALS, INC., TONIX PHARMACEUTICALS HOLDING CORP.
    Inventors: Philip S. Schein, Darryl C. Rideout
  • Analogs of dextromethorphan with balanced receptor activities
    Patent number: 11535596
    Abstract: Substituted analogs of dextromethorphan (DM) are disclosed, which are shown to have substantial binding affinity at both NMDA and sigma-1 receptors, and which are degraded by human liver enzymes more slowly than dextromethorphan. The analogs are useful as alternatives to dextromethorphan, and can provide the same benefits without requiring co-administration of a cytochrome P-450 enzyme inhibitor.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: December 27, 2022
    Assignee: Center for Neurologic Study
    Inventors: Richard Alan Smith, Darryl C. Rideout, Kathleen J. Myers, Andrew Kawasaki
  • Materials amd methods for buffering active chlorine solutions
    Patent number: 11317632
    Abstract: The invention provides buffers stable to oxidants, including chlorine and hypochlorous acid, which are usable in the pH range 3-7. The invention also provides stable, buffered solutions comprising hypochlorous acid, having a pH between 3 and 7, and disposable wiping articles impregnated with these solutions.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: May 3, 2022
    Assignee: Pharmocon LLC
    Inventors: John F O'Connell, Jr., James P Demers, Darryl C Rideout
  • Analogs of Dextromethorphan with Balanced Receptor Activities
    Publication number: 20220064122
    Abstract: Substituted analogs of dextromethorphan (DM) are disclosed, which are shown to have substantial binding affinity at both NMDA and sigma-1 receptors, and which are degraded by human liver enzymes more slowly than dextromethorphan. The analogs are useful as alternatives to dextromethorphan, and can provide the same benefits without requiring co-administration of a cytochrome P-450 enzyme inhibitor.
    Type: Application
    Filed: August 30, 2021
    Publication date: March 3, 2022
    Applicant: The Center for Neurologic Study
    Inventors: Richard Alan Smith, Darryl C. Rideout, Kathleen J. Meyers, Andrew Kawasaki
  • RADIO-AND CHEMO-PROTECTIVE COMPOUNDS
    Publication number: 20210388011
    Abstract: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 16, 2021
    Inventors: Philip S. Schein, Darryl C. Rideout
  • MATERIALS AMD METHODS FOR BUFFERING ACTIVE CHLORINE SOLUTIONS
    Publication number: 20190320658
    Abstract: The invention provides buffers stable to oxidants, including chlorine and hypochlorous acid, which are usable in the pH range 3-7. The invention also provides stable, buffered solutions comprising hypochlorous acid, having a pH between 3 and 7, and disposable wiping articles impregnated with these solutions.
    Type: Application
    Filed: January 17, 2018
    Publication date: October 24, 2019
    Applicant: Pharmocon LLC
    Inventors: John F. O'Connell, JR., James P. Demers, Darryl C. Rideout
  • Drugs effective against retroviruses
    Patent number: 5177083
    Abstract: A method to treat or prevent retroviral infection by administering a novel conjugate is described. Lucifer Yellow and its analogs are conjugated to compounds having carbonyl functional groups for reaction with the semicarbazide moiety of Lucifer Yellow to obtain the semicarbazone conjugate.
    Type: Grant
    Filed: September 11, 1989
    Date of Patent: January 5, 1993
    Assignee: The Scripps Clinic and Research Foundation
    Inventors: Darryl C. Rideout, John Elder
  • In situ active compound assembly
    Patent number: 4812449
    Abstract: Differences in microenvironments associated with various cells and other conditions in this environment are used to advantage in effecting the in situ construction of biologically active agents at target locations in preference to surroundings which are desired to be unaffected.
    Type: Grant
    Filed: October 14, 1987
    Date of Patent: March 14, 1989
    Assignee: Scripps Clinic and Research Foundation
    Inventor: Darryl C. Rideout